Diane Dragaud, Author at News from the ECOG-ACRIN Cancer Research Group

April 15, 2022

April 15, 2022

Categories

Active Clinical Trials

Now Enrolling: ECOG-ACRIN Opens a New NCI-MATCH Treatment Arm for dMMR and LAG-3-Positive Cancers as it Continues to Locate Patients with BRAF Mutations

The ground-breaking NCI-MATCH precision medicine cancer trial continues to offer treatment opportunities for adult patients with relapsed, refractory cancers. Lead investigators Nilo Azad, MD, and April Salama, MD, discuss Arms Z1M and H.

April 15, 2022

April 15, 2022

Categories

Special Topics

Enrollment in TMIST Breast Cancer Screening Trial Surpasses Halfway Mark; Recruitment of Women from Diverse Backgrounds is Key to Success

Enrollment doubles in past 17 months due to specific efforts — Black participation rises above 20%

April 15, 2022

April 15, 2022

Categories

Active Clinical Trials

NCI-MATCH: The Blueprint for Future Precision Medicine Trials

In an enormous undertaking, ECOG-ACRIN and the NCI have built the knowledge base and infrastructure for future precision medicine trials. The new Genomics Subcommittee is offering expertise moving forward.

February 24, 2022

February 24, 2022

Categories

Trial Results

Trial Results: Copanlisib in Patients with PIK3CA-Mutated Tumors

The first published results of a platform trial of PIK3CA mutations across multiple tumor types appear in the Journal of Clinical Oncology. The data are from the NCI-MATCH precision medicine trial.

January 26, 2022

January 26, 2022

Categories

Trial Results

Trial Results: Journal of Clinical Oncology Publishes Final Results of E3311 Phase II Trial for Head and Neck Cancer

A new post-surgery approach for treating HPV-related throat cancer uses less radiation safely and spares the majority of patients from chemotherapy

December 22, 2021

December 22, 2021

Categories

Trial Results

ECOG-ACRIN Research at ASH 2021

Researchers with the Leukemia, Lymphoma, and Myeloma Committees presented a range of findings pertaining to treatments, patient-reported outcomes, and genomics

November 16, 2021

November 16, 2021

Categories

Trial Results

Trial Results: ASCO Highlights Practice-Changing Results in Melanoma

The phase 3 DREAMseq clinical trial provides strong evidence for starting treatment with combination immunotherapy then giving targeted therapy if the disease progresses in patients with BRAF V600 mutant metastatic melanoma

September 30, 2021

Categories

Active Clinical Trials

NCI-MATCH Eliminates the Need for a Formal Referral Letter from the Laboratories

Removing one of several steps will help speed the process for identifying patients who may be eligible to enroll for treatment in NCI-MATCH

May 28, 2021

Categories

People

ECOG-ACRIN Names Vanderbilt University’s Christine Lovly as Its 2021 Young Investigator of the Year

Dr. Lovly is the recipient of the 2021 ECOG-ACRIN Young Investigator Award, a highly prestigious recognition of research excellence

May 28, 2021

May 28, 2021

Categories

Trial Results

ECOG-ACRIN and PrECOG Research at ASCO 2021

Researchers with the ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present a wide range of research findings at the 2021 ASCO Annual Meeting

April 27, 2021

Categories

Active Clinical Trials

Trial Spotlight: Search for patients intensifies with the opening of a new NCI-MATCH treatment arm

In this interview, Dr. Peter O'Dwyer urges physicians, sites, and testing laboratories to redouble efforts to locate patients for 12 open arms

December 14, 2020

Categories

People

ECOG-ACRIN Names University of Pennsylvania’s Bonnie Ky As Its Young Investigator of the Year

Already among the most influential thought leaders in cardio-oncology, Dr. Ky is the first in this field to receive the Group’s highest research distinction